10 completed, 5 recruiting, 2 terminated, 2 unknown. 20 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 20 | Completed 10, Recruiting 5, Terminated 2, Unknown 2, Withdrawn 1 |
| Phase 2 | 2 | Recruiting 1, Unknown 1 |
Follow Hodgkin Lymphoma: new trials by email Literature Review of Hodgkin Lymphoma trials Research Report on Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma 20 Gy Involved site radiotherapy, 30 Gy Involved site radiotherapy - Hodgkin Lymphoma | Phase 3 | Recruiting | Fondazione Italiana Linfomi - ETS | 518 | 2026-07-10 | 2026-08-27 |
| Wisconsin Ginseng for Decreasing Cancer Related Fatigue American Ginseng, Placebo Administration, Questionnaire Administration - Malignant Solid Neoplasm, Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | Mayo Clinic | 222 | 2024-08-01 | 2026-10-20 |
| A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL) JS004 in combination with Toripalimab, Bendamustine or gemcitabine - Hodgkin Lymphoma | Phase 3 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 185 | 2023-12-28 | 2025-02-28 |
| Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma Brentuximab Vedotin 50 MG [Adcetris] - Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 2 / Phase 3 | Recruiting | Hospital Regional de Alta Especialidad del Bajio | 20 | 2022-10-18 | 2025-03-12 |
| Brentuximab Vedotin in Early Stage Hodgkin Lymphoma Involved site radiotherapy, Doxorubicin, Bleomycin - Hodgkin Lymphoma | Phase 3 | Recruiting | University College, London | 1042 | 2022-04-14 | 2026-07-08 |
| A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation AB-205, Placebo - Hodgkin Lymphoma, Non Hodgkin Lymphoma | Phase 3 | Terminated | Angiocrine Bioscience | 130 | 2022-02-21 | 2025-02-04 |
| Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma Camrelizumab and Decitabine - Hodgkin Lymphoma | Phase 2 / Phase 3 | Unknown | Chinese PLA General Hospital | 100 | 2019-09-01 | 2020-08-12 |
| To Decrease Fatigue With Light Therapy Light therapy intensity 1, Light therapy intensity 2 - Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | Phase 3 | Completed | The Netherlands Cancer Institute | 166 | 2017-09-20 | 2020-09-01 |
| FIL Study on ABVD DD-DI as Upfront Therapy in HL. Doxorubicin, Bleomycin, Vinblastine - Hodgkin Lymphoma | Phase 3 | Completed | Fondazione Italiana Linfomi - ETS | 500 | 2017-08-01 | 2025-08-08 |
| Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) pembrolizumab, brentuximab vedotin - Hodgkin Lymphoma | Phase 3 | Completed | Merck Sharp & Dohme LLC | 304 | 2016-05-23 | 2026-02-18 |
| Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies Radiation, Cyclophosphamide, Donor Lymphocyte Infusion (DLI) - Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia | Phase 3 | Completed | Northwell Health | 10 | 2014-12-01 | 2022-04-07 |
| Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11) ABVD + FDG-PET/CT Scan treatment adaptation, BEACOPPesc - Hodgkin Lymphoma | Phase 3 | Withdrawn | European Organisation for Research and Treatment of Cancer - EORTC | 2013-05-01 | 2021-02-15 | |
| A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma brentuximab vedotin, doxorubicin, bleomycin - Hodgkin Lymphoma | Phase 3 | Completed | Takeda | 1334 | 2012-11-09 | 2026-02-27 |
| Double Cord Versus Haploidentical (BMT CTN 1101) Haploidentical Bone Marrow Transplant, Double Umbilical Cord Blood Transplant - Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia | Phase 3 | Completed | Medical College of Wisconsin | 368 | 2012-06-01 | 2021-12-01 |
| HD17 for Intermediate Stage Hodgkin Lymphoma BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone), ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine), 30Gy IF-RT (Involved-Field Radiotherapy) - Hodgkin Lymphoma | Phase 3 | Completed | University of Cologne | 1100 | 2012-01-13 | 2020-04-06 |
| HD16 for Early Stage Hodgkin Lymphoma ABVD (Adriamycin, Bleomycin, Vincristine, Dacarbazine), 20 Gy IFRT (Involved Field Radiotherapy) - Hodgkin Lymphoma | Phase 3 | Unknown | University of Cologne | 1150 | 2009-11-01 | 2020-11-04 |
| R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma Rituximab, Involved field irradiation - Hodgkin Lymphoma | Phase 3 | Terminated | Fondazione Michelangelo | 112 | 2009-09-01 | 2021-08-19 |
| Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma Sirolimus, Methotrexate, Tacrolimus - Non-hodgkin Lymphoma, Hodgkin Lymphoma | Phase 3 | Completed | Dana-Farber Cancer Institute | 139 | 2009-06-01 | 2019-02-01 |
| Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma Bleomycin, Etoposide, Doxorubicin - Hodgkin Lymphoma | Phase 3 | Completed | Fondazione Michelangelo | 331 | 2000-03-01 | 2015-08-13 |
| Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease bleomycin sulfate, dacarbazine, doxorubicin hydrochloride - Hodgkin Lymphoma | Phase 3 | Completed | NCIC Clinical Trials Group | 405 | 1994-01-25 | 2020-04-14 |
Hodgkin Disease (20) · Lymphoma, Non-Hodgkin (5) · Lymphoma (3) · Leukemia, Myeloid, Acute (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Burkitt Lymphoma (1) · Graft vs Host Disease (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1)
Hemic and Lymphatic Diseases (20) · Immune System Diseases (20) · Immunoproliferative Disorders (20) · Lymphatic Diseases (20) · Lymphoproliferative Disorders (20) · Neoplasms (20) · Neoplasms by Histologic Type (20) · Lymphoma (17) · Disease Attributes (3) · Hematologic Diseases (3) · Leukemia, Lymphoid (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Chronic Disease (2) · Leukemia (2)
Bleomycin (8) · Dacarbazine (8) · Doxorubicin (8) · Vinblastine (7) · ABVD protocol (4) · Brentuximab Vedotin (4) · Cyclophosphamide (3) · Vincristine (3) · Etoposide (2) · Prednisone (2) · Procarbazine (2) · Radiotherapy (2) · pembrolizumab (2) · Asian ginseng (1) · Bendamustine Hydrochloride (1)
Fondazione Italiana Linfomi - ETS (2) · Fondazione Michelangelo (2) · University of Cologne (2) · Angiocrine Bioscience (1) · Chinese PLA General Hospital (1) · Dana-Farber Cancer Institute (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Hospital Regional de Alta Especialidad del Bajio (1) · Mayo Clinic (1) · Medical College of Wisconsin (1) · Merck Sharp & Dohme LLC (1) · NCIC Clinical Trials Group (1) · Northwell Health (1) · Shanghai Junshi Bioscience Co., Ltd. (1) · Takeda (1)
United States (8) · Italy (6) · Canada (3) · Denmark (3) · United Kingdom (3) · Australia (2) · Belgium (2) · China (2) · Germany (2) · Netherlands (2) · Spain (2) · Brazil (1) · Czechia (1) · France (1) · Hong Kong (1)
Alessandro M Gianni, MD (2) · Andreas Engert, Prof. (2) · Antonio Pinto, MD (1) · Berthe Aleman (1) · Daniel S. Childs, MD (1) · Eveline Bleiker, PhD (1) · Flora van Leeuwen, Prof.dr.ir. (1) · Jane N. Winter, MD (1) · Joel A Brochstein, MD (1) · John Radford (1) · Laurien Daniels, PhD, MD (1) · Lauro Amador Medina (1) · Martin Hutchings (1) · Mary Horowitz, MD, MS (1)
PMID 40135712, PMID 30010775, PMID 41074963, PMID 15837968, PMID 17846017, PMID 21774708, PMID 22149921, PMID 24121121, PMID 24239220, PMID 25964643, PMID 26729448, PMID 29224502, PMID 30200906, PMID 30617130, PMID 31498753, PMID 31945149, PMID 33475736, PMID 33539742, PMID 33721562, PMID 34048680, PMID 34162178, PMID 34273598, PMID 35717166, PMID 35830649, PMID 37088401, PMID 37120135, PMID 37644732, PMID 37794803, PMID 39846144, PMID 40548833, PMID 41350757, PMID 41522540
2009 (1), 2015 (1), 2023 (1), U10HL069294 (1), U24CA076518 (1)